Cardiovascular Systems (CSII) 10-K 23 Aug 18 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2018	Aug. 17, 2018	Dec. 31, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	Cardiovascular Systems Inc
Entity Central Index Key	1,180,145
Document Type	10-K
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Public Float			$ 761.7
Entity Common Stock, Shares Outstanding		33,505,560

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Current assets
Cash and cash equivalents	$ 116,260	$ 107,912
Accounts receivable, net	31,225	28,472
Inventories	16,605	16,897
Marketable securities	544	704
Prepaid expenses and other current assets	2,977	5,074
Total current assets	167,611	159,059
Property and equipment, net	27,744	29,696
Patents, net	5,231	5,056
Other assets	2,766	129
Total assets	203,352	193,940
Current liabilities
Accounts payable	10,441	10,736
Accrued expenses	25,776	30,236
Deferred Revenue, Current	1,243	0
Total current liabilities	37,460	40,972
Long-term liabilities
Financing obligation	21,064	21,100
Deferred revenue	8,946	10,000
Other liabilities	1,412	3,479
Total liabilities	68,882	75,551
Commitments and contingencies
Common stock, $0.001 par value; authorized 100,000,000 common shares; issued and outstanding 33,360,032 at June 30, 2018 and 32,849,563 at June 30, 2017	33	33
Additional paid in capital	461,927	447,559
Accumulated other comprehensive income	101	100
Accumulated deficit	(327,591)	(329,303)
Total stockholders’ equity	134,470	118,389
Total liabilities and stockholders’ equity	$ 203,352	$ 193,940

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2018	Jun. 30, 2017
Statement of Financial Position [Abstract]
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	33,360,032	32,792,497
Common stock, shares outstanding	33,360,032	32,792,497

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Document Period End Date	Jun. 30, 2018
Net revenues	$ 217,043	$ 204,906	$ 178,184
Cost of goods sold	39,484	39,441	35,421
Gross profit	177,559	165,465	142,763
Expenses:
Selling, general and administrative	148,569	144,096	162,542
Research and development	26,756	22,911	25,934
Restructuring	0	0	2,364
Legal settlement	0	0	8,000
Total expenses	175,325	167,007	198,840
Income (loss) from operations	2,234	(1,542)	(56,077)
Interest expense	1,717	500	0
Other Income	(1,327)	(336)	(145)
Other (income) and expense, net	390	164	(145)
Income (loss) before income taxes	1,844	(1,706)	(55,932)
Provision for income taxes	132	86	92
Net income (loss)	$ 1,712	$ (1,792)	$ (56,024)
Net loss per common share:
Earnings per common share — basic	$ 0.05	$ (0.06)	$ (1.72)
Earnings per common share — diluted	$ 0.05	$ (0.06)	$ (1.72)
Weighted Average Number of Shares Outstanding, Basic	33,145,140	32,373,709	32,537,621
Weighted average common shares outstanding - diluted (in shares)	33,614,260	32,373,709	32,537,621

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss Statement - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 1,712	$ (1,792)	$ (56,024)
Other comprehensive income (loss):
Unrealized gain on available for sale securities	35	66	20
Adjustment for net gain realized and included in interest income and other, net	(34)	(6)	(70)
Total change in unrealized gain (loss) on available for sale securities	1	60	(50)
Comprehensive income (loss)	$ 1,713	$ (1,732)	$ (56,074)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Total	Common Stock	Additional Paid In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Balance at beginning of period (in shares) at Jun. 30, 2015		31,898,124
Balance at beginning of period at Jun. 30, 2015	$ 139,435,000	$ 32,000	$ 410,700,000	$ 90,000	$ (271,387,000)
Stock-based compensation related to restricted stock awards, net (in shares)		557,756
Stock-based compensation related to restricted stock awards, net	11,986,000	$ 1,000	11,985,000
Exercise of stock options and warrants (in shares)		87,817
Exercise of stock options and warrants	1,006,000	$ 0	1,006,000
Employee stock purchase plan activity (in shares)		248,800
Employee stock purchase plan activity	4,544,000		4,544,000
Unrealized gain on marketable securities	20,000	$ 0	0	20,000	0
Net gain reclassified from accumulated other comprehensive income	(70,000)
Net income (loss)	(56,024,000)				(56,024,000)
Balance at end of period (in shares) at Jun. 30, 2016		32,792,497
Balance at end of period at Jun. 30, 2016	100,897,000	$ 33,000	428,235,000	40,000	(327,411,000)
Stock-based compensation related to restricted stock awards, net (in shares)		(635,018)
Stock-based compensation related to restricted stock awards, net	9,412,000	$ 0	9,412,000
Exercise of stock options and warrants (in shares)		515,164
Exercise of stock options and warrants	5,262,000		5,362,000		(100,000)
Employee stock purchase plan activity (in shares)		176,920
Employee stock purchase plan activity	4,550,000		4,550,000
Unrealized gain on marketable securities	66,000			66,000
Net gain reclassified from accumulated other comprehensive income	(6,000)			(6,000)
Net income (loss)	(1,792,000)				(1,792,000)
Balance at end of period (in shares) at Jun. 30, 2017		32,849,563
Balance at end of period at Jun. 30, 2017	118,389,000	$ 33,000	447,559,000	100,000	(329,303,000)
Stock-based compensation related to restricted stock awards, net (in shares)		295,650
Stock-based compensation related to restricted stock awards, net	9,546,000	$ 0	9,546,000
Exercise of stock options and warrants (in shares)		55,880
Exercise of stock options and warrants	514,000		514,000		0
Employee stock purchase plan activity (in shares)		158,939
Employee stock purchase plan activity	4,308,000		4,308,000
Unrealized gain on marketable securities	35,000			35,000
Net gain reclassified from accumulated other comprehensive income	(34,000)			(34,000)
Net income (loss)	1,712,000				1,712,000
Balance at end of period (in shares) at Jun. 30, 2018		33,360,032
Balance at end of period at Jun. 30, 2018	$ 134,470,000	$ 33,000	$ 461,927,000	$ 101,000	$ (327,591,000)

Consolidated Statements of Cha7

Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Lower range of exercise of stock options and warrants (in usd per share)	$ 7.90	$ 7.90	$ 5.01
Upper range of exercise of stock options and warrants (in usd per share)	12.19	12.37	$ 12.37
Issuance costs
Common Stock
Lower range of exercise of stock options and warrants (in usd per share)	7.90	7.90	$ 5.01
Upper range of exercise of stock options and warrants (in usd per share)	12.19	12.37	$ 12.37
Issuance costs
Additional Paid In Capital
Lower range of exercise of stock options and warrants (in usd per share)	7.90	7.90	$ 5.01
Upper range of exercise of stock options and warrants (in usd per share)	$ 12.19	$ 12.37	$ 12.37
Issuance costs

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Document Period End Date	Jun. 30, 2018
Cash flows from operating activities
Net income (loss)	$ 1,712	$ (1,792)	$ (56,024)
Adjustments to reconcile net income (loss) to net cash used in operations
Depreciation of property and equipment	3,730	3,917	3,686
Provision for (recovery of) doubtful accounts (including note receivable)	(225)	465	725
Amortization of patents	204	218	231
Write-off of patent costs	497	733	168
Loss on disposal of property and equipment	16	158	170
Stock-based compensation	10,302	10,354	12,977
Other	0	138	0
Changes in assets and liabilities
Accounts receivable	(2,878)	(5,809)	7,327
Inventories	292	543	(3,474)
Prepaid expenses and other assets	2,308	(1,823)	728
Accounts payable	104	1,761	(970)
Accrued expenses and other liabilities	(6,577)	725	10,873
Deferred revenue	189	10,000	0
Net cash provided by (used in) operating activities	9,674	19,588	(23,583)
Cash flows from investing activities
Expenditures for property and equipment	(1,956)	(981)	(3,818)
Purchase of investment	(2,538)	0	0
Proceeds from (issuance of) convertible note receivable	318
Proceeds from (issuance of) convertible note receivable		0	(350)
Purchases of marketable securities	0	0	(37)
Sales of marketable securities	194	46	1,249
Costs incurred in connection with patents	(1,113)	(844)	(813)
Net cash used in investing activities	(5,095)	(1,779)	(3,769)
Cash flows from financing activities
Proceeds from the employee stock purchase plan	3,242	3,254	3,142
Exercise of stock options	513	5,263	1,006
Proceeds from financing		20,944	0
Other	14	4	0
Net cash provided by financing activities	3,769	29,465	4,148
Net change in cash and cash equivalents	8,348	47,274	(23,204)
Cash and cash equivalents
Beginning of period	107,912	60,638	83,842
End of period	116,260	107,912	60,638
Noncash investing and financing activities
Change in equipment included in accounts payable	162	(319)	(374)
Change in patent costs included in accounts payable	237	(150)	87
Supplemental cash flow information
Interest paid	$ 1,717	$ 500	$ 0

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Company Description Cardiovascular Systems, Inc. (the “Company”), based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The Company’s Orbital Atherectomy Systems (“OAS”) treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. Principles of Consolidation The consolidated balance sheets and statements of operations, comprehensive loss, changes in stockholders’ equity, and cash flows include the accounts of the Company and its wholly-owned subsidiary, after elimination of all intercompany transactions and accounts. Cash and Cash Equivalents The Company considers all money market funds and other investments purchased with an original maturity of three months or less to be cash and cash equivalents. Accounts Receivable and Allowance for Doubtful Accounts Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the general standard being net 30 days. Collateral or any other security to support payment of these receivables generally is not required. The Company maintains an allowance for doubtful accounts, which is an estimate regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay. Provisions for the allowance for doubtful accounts attributed to bad debt are recorded in general and administrative expenses. The following table shows the allowance for doubtful accounts activity: Amount Balances at June 30, 2015 $ 1,437 Provision for doubtful accounts 375 Write-offs (1,100 ) Balance at June 30, 2016 712 Provision for doubtful accounts 465 Write-offs (313 ) Balance at June 30, 2017 864 Provision for doubtful accounts 125 Write-offs (189 ) Balance at June 30, 2018 $ 800 Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out method of valuation. The establishment of inventory allowances for excess and obsolete inventories is based on estimated exposure on specific inventory items. The Company writes down its inventories as it becomes aware of any situation where the carrying amount exceeds the estimated realizable value based on assumptions about future demands and market conditions. Property and Equipment Property and equipment is carried at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over estimated useful lives of 40 years for the building; five to seven years for production equipment and furniture and fixtures; three years for computer equipment and software; and the shorter of their estimated useful lives or the lease term for leasehold improvements. Expenditures for maintenance and repairs and minor renewals and betterments that do not extend or improve the life of the respective assets are expensed as incurred. All other expenditures for renewals and betterments are capitalized. The assets and related depreciation accounts are adjusted for property retirements and disposals with the resulting gains or losses included in the consolidated statement of operations. Patents The capitalized costs incurred to obtain patents are amortized using the straight-line method over their remaining estimated lives. Patent amortization begins at the time of patent application approval, and does not exceed 20 years. The recoverability of capitalized patent costs is dependent upon the Company’s ability to derive revenue-producing products from such patents or the ultimate sale or licensing of such patent rights. Patent recoverability is regularly reviewed and any patents that are abandoned are written off at the time of abandonment. Long-Lived Assets The Company regularly evaluates the carrying value of long-lived assets for events or changes in circumstances that indicate that the carrying amount may not be recoverable or that the remaining estimated useful life should be changed. An impairment loss is recognized when the carrying amount of an asset exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. The amount of the impairment loss to be recorded, if any, is calculated by the excess of the asset’s carrying value over its fair value. Operating Leases The Company leases its Texas manufacturing facilities under an operating lease agreement. The lease contains rent escalation clauses for which the lease expense is recognized on a straight-line basis over the lease term. Rent expense that is recognized but not yet paid is included in other liabilities on the consolidated balance sheets. Financing Obligation In March 2017, the Company entered into an agreement to lease its Minnesota facility. The lease agreement has an initial term of fifteen years, with four consecutive renewal options of five years each at the Company's option. As the lease terms resulted in a capital lease classification, the Company accounted for the sale and leaseback of its Minnesota facility as a financing transaction where the assets remain on the Company's balance sheet and a financing obligation was recorded for $20,944. As lease payments are made, they will be allocated between interest expense and a reduction of the financing obligation, resulting in a value of the financing obligation that is equivalent to the net book value of the assets at the end of the lease term. At the end of the lease (including any renewal option terms), the Company will remove the assets and financing obligation from its balance sheet. Revenue Recognition The Company sells the majority of its products via direct shipment to hospitals or clinics. The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the sales price is fixed or determinable; and collectability is reasonably assured. Revenue recognition may occur upon shipment or upon delivery to the customer site, based on the contract terms. The Company records estimated sales returns, discounts and rebates as a reduction of net sales. Deferred revenue associated with the upfront payment received under the Company’s distribution agreement with Medikit is recognized in relation to the estimated future sales under the agreement. The short term portion represents the expected amount of deferred revenue that will be recognized over the next year. The estimate of future sales under contract will continue to be assessed and adjusted accordingly. Costs related to products delivered are recognized in the period the revenue is recognized. Cost of goods sold consists primarily of raw materials, direct labor, and manufacturing overhead. Deferred Revenue In November 2016, the Company signed an exclusive distribution agreement with Medikit Co., Ltd. (“Medikit”) to sell its Coronary and Peripheral OAS in Japan. To secure exclusive distribution rights, Medikit made an upfront payment of $10,000 to the Company, which is refundable based on the occurrence of certain events during the term of the agreement. The Company has classified the payment as current or long-term based on its expectation of when revenue will be recognized and is re-evaluated on a quarterly basis. Medikit also provides advance payments for orders under the terms of the agreement, and, therefore, deferred revenue is recorded until products are accepted by Medikit. Warranty Costs The Company provides its customers with the right to receive a replacement if a product is determined to be defective at the time of shipment. Warranty reserve provisions are estimated based on Company experience, volume, and expected warranty claims. Warranty reserve, provisions and claims were as follows: Amount Balances at June 30, 2015 $ 126 Provision 490 Claims (471 ) Balance at June 30, 2016 145 Provision 1,733 Claims (1,361 ) Balance at June 30, 2017 517 Provision 328 Claims (713 ) Balance at June 30, 2018 $ 132 Pump Recall In April 2017, the Company initiated a voluntary recall of one type of its saline infusion pumps that resulted in a reserve of approximately $1,535 incurred in fiscal 2017, relating to estimated costs of the recall. Litigation and Contingent Liabilities The Company and its operations from time to time are, and in the future may be, parties to or targets of lawsuits, claims, investigations, and proceedings, which are handled and defended in the ordinary course of business. The Company accrues a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When a single amount cannot be reasonably estimated but the cost can be estimated within a range, the Company accrues an amount based on management’s best estimate considering all facts and circumstances. The Company expenses legal costs, including those expected to be incurred in connection with a loss contingency, as incurred. Medical Device Excise Tax The Patient Protection and Affordable Care Act of 2010 imposed a medical device excise tax on medical device manufacturers on their sales in the United States of certain devices, which was effective January 1, 2013. The excise tax is 2.3% of the taxable base and applied to a substantial majority of the Company’s sales. Effective January 1, 2016, the excise tax was suspended until the end of 2017, and in January 2018, another temporary two year suspension of the tax was passed, extending the suspension to December 31, 2019. The Company incurred $1,273 of expense related to the tax during the year ended June 30, 2016. Income Taxes Deferred income taxes are recorded to reflect the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts based on enacted tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Developing a provision for income taxes, including the effective tax rate and the analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets. The Company’s judgment and tax strategies are subject to audit by various taxing authorities. Accounting guidance requires that accounting for uncertainty in income taxes is recognized in the financial statements. The guidance provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. The guidance also provides rules on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Research and Development Expenses Research and development expenses include costs associated with the design, development, testing, enhancement and regulatory approval of the Company’s products. Research and development expenses include employee compensation (including stock-based compensation), supplies and materials, consulting expenses, patent amortization, travel and facilities overhead. The Company also incurs significant expenses to operate clinical trials, including trial design, third-party fees, clinical site reimbursement, data management and travel expenses. Research and development expenses are expensed as incurred. Expenses associated with patent applications are capitalized and amortized using the straight-line method over their remaining estimated lives. Patent amortization begins at the time of patent application approval, and does not exceed 20 years . Concentration of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains its cash balances primarily with one financial institution. These balances exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy and that credit risk related to accounts receivable is limited due to a large customer base. Marketable Securities The Company’s marketable securities consist solely of available-for-sale securities and were valued in accordance with the fair value measurement guidance discussed below. Available-for-sale securities are carried at fair value with unrealized gains and losses reported as a component of stockholders’ equity as accumulated other comprehensive income (loss), net of tax. Realized gains and losses, if any, are calculated on the specific identification method and are included in interest and other, net in the consolidated statements of operations. Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported in equity as accumulated other comprehensive income (loss). Cost Method Investments When the Company controls less than 20% of the decision-making ability over the operations of the investee, the investment is accounted for at cost. Cost method investments are reviewed quarterly for any events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. When the fair value declines below the cost, an impairment loss is recognized unless it is considered temporary. Impairment is considered to be other than temporary if the length of time it will take for the investment’s value to exceed its cost is greater than the Company’s intent and ability to hold the investment. Fair Value Measurements Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows: Level 1 Inputs — quoted prices in active markets for identical assets and liabilities Level 2 Inputs — observable inputs other than quoted prices in active markets for identical assets and liabilities Level 3 Inputs — unobservable inputs As of June 30, 2018 , the Company believes that the carrying amounts of its other financial instruments, including accounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4 for additional information. Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and these differences could be material. Stock-Based Compensation The Company has stock-based compensation plans, which include stock options, nonvested share awards, and an employee stock purchase plan. Fair value of option awards is determined using option-pricing models, fair value of nonvested share awards with market conditions is determined using the Monte Carlo simulation, and fair value of nonvested share awards that vest based upon performance or service conditions is determined by the closing market price of the Company’s stock on the date of grant. Stock-based compensation expense is recognized ratably over the requisite service period for the awards expected to vest. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The Company has completed an adoption plan, which included a review of customer contracts, applying the five-step model of the new standard to the customer contracts and comparing the results to the Company’s current accounting. The Company has elected the modified retrospective method of adoption, which the Company anticipates will not result in a material adjustment to retained earnings. The Company’s revenue recognition will remain largely unchanged given the majority of the Company’s revenue arrangements consist of a single performance obligation that will be recognized at a point in time when control passes to the customer. As a result, the Company does not anticipate a material impact on the amount and timing of revenue recognized in the Company’s consolidated financial statements. The Company is also implementing new internal controls around the judgments needed to address risks associated with applying the five-step model, which includes identifying performance obligations and judgments made related to variable consideration. Effective July 1, 2018, the Company will be revising its revenue recognition accounting policy and disclosures to reflect the requirements of the amended revenue recognition guidance. The Company will continue to monitor any modifications or interpretations communicated by the FASB that may impact any of its final assessments related to the guidance. In January 2016, the FASB issued ASU 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities,” which revises the accounting requirements related to the classification and measurement of investments in equity securities and the presentation of certain fair value changes for financial liabilities measured at fair value. The update also changes certain disclosure requirements associated with the fair value of financial instruments. These changes will require an entity to measure, at fair value, investments in equity securities and recognize the changes in fair value within net income. ASU 2016-01 will be applied on a modified retrospective basis to all outstanding instruments, with an adjustment recorded to opening retained earnings as of the beginning of the first period in which the guidance becomes effective. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. The guidance is effective for the Company on July 1, 2018. The Company does not anticipate a material impact on its financial statements upon adoption. In February 2016, the FASB issued ASU 2016-02, “Leases.” The guidance requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, and should be applied using a modified retrospective approach. Early adoption is permitted. The guidance is effective for the Company on July 1, 2019. The Company is currently evaluating the timing, method of adoption and impact of the new lease guidance on its financial statements. In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which revises guidance for the accounting for credit losses on financial instruments within its scope. The new standard introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new approach to estimating credit losses (referred to as the current expected credit losses model) applies to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases and off-balance-sheet credit exposures. ASU 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted and should be applied as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The guidance is effective for the Company on July 1, 2020. The Company does not anticipate a material impact on its financial statements upon adoption. In May 2017, the FASB issued ASU 2017-09, “Scope of Modification Accounting” which clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. The guidance is effective for annual periods, and interim periods within those annual periods beginning after December 15, 2017, with early adoption permitted. The Company does not anticipate a material impact on its financial statements upon adoption.

Selected Consolidated Financial

Selected Consolidated Financial Statement Information	12 Months Ended
	Jun. 30, 2018
Quarterly Financial Information Disclosure [Abstract]
Selected Consolidated Financial Statement Information	2. Selected Consolidated Financial Statement Information Accounts Receivable, Net Accounts receivable consists of the following: June 30, 2018 2017 Accounts receivable $ 32,025 $ 29,336 Less: Allowance for doubtful accounts (800 ) (864 ) Accounts receivable, net $ 31,225 $ 28,472 Inventories Inventories consist of the following: June 30, 2018 2017 Raw materials $ 6,820 $ 7,898 Work in process 1,315 1,221 Finished goods 8,470 7,778 Inventories $ 16,605 $ 16,897 Property and Equipment, Net Property and equipment consists of the following: June 30, 2018 2017 Land $ 500 $ 500 Building 22,420 22,420 Equipment 16,510 16,502 Furniture 2,709 2,709 Leasehold improvements 438 86 Construction in progress 1,110 421 43,687 42,638 Less: Accumulated depreciation (15,943 ) (12,942 ) Total Property and equipment, net $ 27,744 $ 29,696 On December 29, 2016, the Company entered into a Purchase and Sale Agreement, as subsequently amended (collectively, the “Sale Agreement”), with Krishna Holdings, LLC (the “Buyer”), providing for the sale to Buyer of the Company’s headquarters facility in St. Paul, Minnesota (the “Facility”), for a cash purchase price of $21,500 . On March 30, 2017, the sale of the Facility under the Sale Agreement closed. The Company received proceeds of approximately $20,944 ( $21,500 , less $556 of transaction expenses). The net proceeds are to be used for working capital and general corporate purposes. In connection with the sale, the Company recorded an impairment charge of $158 . Under the Sale Agreement, the Company entered into a Lease Agreement (the “Lease Agreement”) with Krishna Holdings, LLC, Apex Holdings, LLC, Kashi Associates, LLC, Keva Holdings, LLC, S&V Ventures, LLC, Polo Group LLC, SPAV Holdings LLC, Star Associates LLC, and The Global Villa, LLC. As the lease terms resulted in a capital lease classification, the Company accounted for the sale and leaseback of the Facility as a financing transaction where the assets remain on the Company’s balance sheet. See Note 3 for further discussion on future payment obligations under the Lease Agreement. Patents, net Patents, net consist of the following: June 30, 2018 2017 Patents $ 6,435 $ 6,056 Less: Accumulated amortization (1,204 ) (1,000 ) Total Patents, net $ 5,231 $ 5,056 As of June 30, 2018 , future estimated amortization of patents is as follows: 2019 $ 199 2020 193 2021 191 2022 181 2023 174 Thereafter 4,293 $ 5,231 This future amortization expense is an estimate. Actual amounts may vary from these estimated amounts due to additional intangible asset acquisitions, approval of patents-in-process, potential impairment, change in useful life or other events. Accrued Expenses Accrued expenses consist of the following: June 30, 2018 2017 Commissions $ 7,234 $ 8,217 Salaries and bonus 6,624 8,247 Accrued vacation 3,557 3,436 Accrued excise, sales and other taxes 3,522 3,497 Legal settlement 1,847 1,814 Clinical studies 1,422 657 Accrued litigation — 2,600 Other accrued expenses 1,570 1,768 Total Accrued expenses $ 25,776 $ 30,236 Legal Settlement On June 28, 2016, the Company entered into a Settlement Agreement (the “Settlement Agreement”) with the United States of America, acting through the Department of Justice (the “DOJ”) and on behalf of the Office of Inspector General of the Department of Health and Human Services, and Travis Thams, to resolve the investigation by the DOJ and the civil action underlying such investigation. Under the Settlement Agreement, the Company agreed to pay $8,000 (the “Settlement Amount”), as follows: an initial payment of $3,000 , paid on July 1, 2016, with the remaining $5,000 , which bears interest at 1.8% per annum, payable in 11 equal quarterly installments, beginning January 1, 2017. The amount payable within the next twelve months is included in accrued expenses (as noted in the table above) with the long-term portion included in other liabilities (as noted in the table below). Under the Settlement Agreement, if the Company makes a single payment in excess of $2,000 , which payment is not covered by an insurance policy, in settlement of any claims before paying the full Settlement Amount, the remaining unpaid balance of the Settlement Amount will become immediately due and payable, with interest accruing on the unpaid principal portion at an interest rate of 1.8% per annum. Restructuring On March 31, 2016, the Company announced a restructuring to reduce costs as part of its plan to progress towards profitability and positive cash flow. As a result, the Company recorded a restructuring expense of $2,364 during the year ended June 30, 2016, which was comprised of severance and other employee related costs. There was $22 and $169 of accrued restructuring costs recorded as accrued expenses on the consolidated balance sheet as of June 30, 2018 and June 30, 2017, respectively. Other Liabilities The Company’s non-current other liabilities consist of the following: June 30, 2018 2017 Legal settlement $ 467 $ 2,314 Deferred compensation 395 519 Deferred grant incentive 460 473 Other liabilities 90 173 Total Other liabilities $ 1,412 $ 3,479

Debt

Debt	12 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	3. Debt Revolving Credit Facility On March 31, 2017, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). The Loan Agreement provides for a senior, secured revolving credit facility (the “Revolver”) of $40,000 (the “Maximum Dollar Amount”). Advances under the Revolver may be made from time to time up to the Maximum Dollar Amount, subject to certain borrowing limitations. The Revolver has a maturity date of March 31, 2020 and bears interest at a floating per annum rate equal to the Wall Street Journal prime rate, less 0.25% . Interest on borrowings is due monthly and the principal balance is due at maturity. Borrowings up to $10,000 are available on a non-formula basis. Borrowings above $10,000 are based on (i) 85% of eligible domestic accounts receivable, and (ii) the lesser of 50% of eligible inventory or $5,000 , subject to adjustment as defined in Loan Agreement. Upon the Revolver’s maturity, any outstanding principal balance, unpaid accrued interest, and all other obligations under the Revolver will be due and payable. The Company will incur a fee equal to 1% of the Maximum Dollar Amount upon termination of the Loan Agreement or the Revolver for any reason prior to the maturity date, unless refinanced with SVB. The Company’s obligations under the Loan Agreement are secured by certain of the Company’s assets, including, among other things, accounts receivable, deposit accounts, inventory, equipment, general intangibles and records pertaining to the foregoing. The collateral does not include the Company’s intellectual property, but the Company has agreed not to encumber its intellectual property without the consent of SVB. The Loan Agreement contains customary covenants limiting the Company’s ability to, among other things, incur debt or liens, make certain investments and loans, enter into transactions with affiliates, undergo certain fundamental changes, dispose of assets, or change the nature of its business. In addition, the Loan Agreement contains financial covenants requiring the Company to maintain, at all times when any amounts are outstanding under the Revolver, either (i) minimum unrestricted cash at SVB and unused availability on the Revolver of at least $10,000 or (ii) minimum trailing three-month Adjusted EBITDA of $1,000 . If the Company does not comply with the various covenants under the Loan Agreement, the interest rate on outstanding amounts will increase by 5% and SVB may, subject to various customary cure rights, decline to provide additional advances under the Revolver, require the immediate payment of all amounts outstanding under the Revolver, and foreclose on all collateral. Under the Loan Agreement, the Company paid SVB a non-refundable commitment fee of $80 , which is being amortized to interest expense over the term of the Loan Agreement. The Company is required to pay a fee equal to 0.35% per annum on the unused portion of the Revolver, payable quarterly in arrears. SVB’s obligations to advance funds under the Revolver are subject to an initial collateral examination to be completed within 90 days of the effective date of the Loan Agreement. The Company is not obligated to draw any funds under the Revolver and no amounts were outstanding as of June 30, 2018 and 2017. Financing Obligation In connection with the sale of the Facility, the Company entered into a Lease Agreement to lease the Facility. The Lease Agreement has an initial term of 15 years , with four consecutive renewal options of 5 years each at the Company’s option, with a base annual rent in the first year of $1,638 and annual escalations of 3% thereafter. Rent during subsequent renewal terms will be at the then fair market rental rate. The effective interest rate is 7.89% . Future payments under the initial term of the Lease Agreement as of June 30, 2018 are as follows: 2019 $ 1,699 2020 1,750 2021 1,803 2022 1,857 2023 1,913 Thereafter 19,375 $ 28,397

Fair Value

Fair Value	12 Months Ended
	Jun. 30, 2018
Compensation Related Costs [Abstract]
Deferred Compensation	4. Fair Value The available-for-sale marketable securities are primarily comprised of investments with a fixed income and equity investments and consist of the following, measured at fair value on a recurring basis: Fair Value Measurements as of June 30, 2018 Using Inputs Considered as Fair Value Level 1 Level 2 Level 3 Mutual funds $ 544 199 345 $ — Total marketable securities $ 544 199 345 $ — Fair Value Measurements as of June 30, 2017 Using Inputs Considered as Fair Value Level 1 Level 2 Level 3 Mutual funds $ 704 281 423 $ — Total marketable securities $ 704 281 423 $ — During the years ended June 30, 2018 and 2017 , there were no purchases of available-for-sale securities and $194 and $40 , respectively, of available-for-sale securities that were sold. There were no other-than-temporary impairments during the years ended June 30, 2018 and 2017 . During the years ended June 30, 2018 and 2017 , there was a realized gain of $34 and $6 that was recorded within interest income and other, net on the consolidated statement of operations. There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the year ended June 30, 2018 . Any transfers between levels are recognized on the date of the event or when a change in circumstances causes a transfer. Cost Method Investment The Company holds a cost method investment measured at fair value on a nonrecurring basis and is classified as a Level 3 investment. As of June 30, 2018, the cost of the investment was $2,538 . There were no identified events or changes that had a significant adverse effect on the fair value of the investment. The investment is recorded within other long term assets on the consolidated balance sheet.

Stock Options and Restricted St

Stock Options and Restricted Stock Awards	12 Months Ended
	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options and Restricted Stock Awards	5. Stock Options and Restricted Stock Awards On November 15, 2017, the Company’s stockholders approved the 2017 Equity Incentive Plan (the “2017 Plan”) for the purpose of granting equity awards to employees, directors, and consultants. The 2017 Plan replaced the 2014 Equity Incentive Plan (the “2014 Plan”), and no further equity awards may be granted under the 2014 Plan or the 2007 Equity Incentive Plan (the “2007 Plan”) (the 2017 Plan, 2014 Plan and the 2007 Plan are collectively referred to as the “Plans”). The 2017 Plan allows for the granting of up to 3,607,523 shares of common stock as approved by the Board of Directors or committees thereof in the form of nonqualified or incentive stock options, restricted stock awards, restricted stock unit awards, performance share awards, performance unit awards or stock appreciation rights to officers, directors, consultants and employees of the Company. Stock Options All options granted under the Plans become exercisable over periods established at the date of grant. The option exercise price is generally not less than the estimated fair market value of the Company’s common stock at the date of grant, as determined by the Company’s management and Board of Directors. In addition, the Company has granted nonqualified stock options to a director outside of the Plans. Stock option activity is as follows: Number of Options Weighted Average Exercise Price Options outstanding at June 30, 2015 699,872 $ 10.32 Exercised (87,817 ) $ 11.46 Forfeited or expired (5,176 ) $ 12.37 Options outstanding at June 30, 2016 606,879 $ 10.14 Exercised (519,297 ) $ 10.33 Expired (9,381 ) $ 8.83 Options outstanding at June 30, 2017 78,201 $ 9.07 Exercised (55,880 ) $ 9.20 Options outstanding at June 30, 2018 22,321 $ 8.75 As of June 30, 2018 , all options were fully vested. An employee’s vested options must be exercised at or within 90 days of termination to avoid forfeiture. The Company determined the fair value of options using the Black-Scholes option pricing model. The estimated fair value of options, including the effect of estimated forfeitures, was recognized as expense on a straight-line basis over the options’ vesting periods. There were no options granted during the years ended June 30, 2018 , 2017 or 2016 . The aggregate intrinsic value of a stock option award is the amount by which the market value of the underlying stock exceeds the exercise price of the award. The aggregate intrinsic value for vested and outstanding options at June 30, 2018 , 2017 and 2016 , was $527 , $1,811 and $4,025 , respectively. The total aggregate intrinsic value of options exercised during the years ended June 30, 2018 , 2017 and 2016 , was $1,095 , $7,955 , and $417 , respectively. Cash received from option exercises was $514 , $5,363 and $1,006 for the years ended June 30, 2018 , 2017 and 2016 , respectively. The weighted average remaining contractual life of options outstanding at June 30, 2018 was 0.67 years . Shares supporting option exercises are sourced from new share issuances. Restricted Stock The fair value of each restricted stock award was equal to the fair market value of the Company’s common stock at the date of grant. Vesting of time based restricted stock awards ranges from one to three years. The estimated fair value of restricted stock awards, including the effect of estimated forfeitures, is recognized on a straight-line basis over the restricted stock’s vesting period. Restricted stock award activity is as follows: Number of Shares Weighted Average Grant Date Fair Value Outstanding at June 30, 2015 843,094 $ 25.16 Granted 522,415 $ 19.30 Forfeited (230,710 ) $ 24.83 Vested (487,226 ) $ 22.27 Outstanding at June 30, 2016 647,573 $ 23.24 Granted 258,346 $ 21.80 Forfeited (103,140 ) $ 22.11 Vested (316,195 ) $ 24.21 Outstanding at June 30, 2017 486,584 $ 21.26 Granted 290,856 $ 27.93 Forfeited (68,499 ) $ 22.76 Vested (253,725 ) $ 22.87 Outstanding at June 30, 2018 455,216 $ 24.77 Total fair value of time-based restricted stock that vested during fiscal 2018 , 2017 and 2016 was $5,803 , $7,655 , and $10,851 , respectively. Estimated pre-vesting forfeitures are considered in determining stock-based compensation expense. As of June 30, 2018 , 2017 and 2016 , the Company estimated its weighted average forfeiture rate at 15.2% , 17.1% and 17.0% , respectively. As of June 30, 2018 , there was approximately $8,171 of total unrecognized compensation expense, net of the effect of estimated forfeitures, related to nonvested restricted stock awards, which is expected to be recognized over a weighted-average period of 1.6 years . Performance-Based Restricted Stock The Company also grants performance-based restricted stock awards to certain executives and other management. Fiscal 2018 awards vest based on the Company’s total shareholder return relative to total shareholder return of the peer group (a market condition), as measured by the closing prices of the stock of the Company and its peer group for the 90 trading days preceding July 1, 2017 compared to the closing prices for the 90 trading days preceding July 1, 2020. Fiscal 2017 awards vest based on the Company’s total shareholder return relative to total shareholder return of the peer group (a market condition), as measured by the closing prices of the stock of the Company and its peer group for the 90 trading days preceding July 1, 2016 compared to the closing prices for the 90 trading days preceding July 1, 2019. Fiscal 2016 awards included grants that vested based upon the achievement of certain thresholds measuring total shareholder return during periods within the fiscal year as compared to a pre-determined peer group of companies, and grants that vested based upon achievement of certain thresholds measuring annual revenue growth during the fiscal year as compared to a pre-determined peer group of companies. The aggregate maximum shares granted were as follows: Performance Measurement 2018 2017 2016 Total shareholder return 278,889 336,826 156,509 Annual revenue growth N/A N/A 156,509 The results of the Company’s performance based restricted stock awards for fiscal 2016 was a 0% achievement and zero shares vesting for both performance measurements. Performance-based restricted stock award activity is as follows: Number of Weighted Average Outstanding at June 30, 2015 152,224 $ 22.03 Granted 313,018 $ 16.67 Forfeited (52,680 ) $ 28.64 Vested (102,451 ) $ 25.58 Outstanding at June 30, 2016 310,111 $ 16.67 Granted 336,826 $ 11.97 Forfeited (328,353 ) $ 16.41 Outstanding at June 30, 2017 318,584 $ 11.97 Granted 278,889 $ 13.63 Forfeited (66,295 ) $ 13.17 Outstanding at June 30, 2018 531,178 $ 12.69 Total fair value of performance-based restricted stock that vested during fiscal 2018 , 2017 and 2016 was $0 , $0 , and $2,621 , respectively. Estimated pre-vesting forfeitures are considered in determining stock-based compensation expense. As of June 30, 2018 , there was approximately $2,791 of total unrecognized compensation expense related to nonvested performance-based restricted stock awards, which is expected to be recognized over a weighted-average period of 1.6 years . Restricted Stock Units The Company grants restricted stock units to members of its Board of Directors. Restricted stock units represent the right to receive payment in the form of shares of the Company’s common stock or in cash at the Company’s option. Restricted stock unit payments would occur within 30 days following the six month anniversary of the date that the director ceases to serve on the Board of Directors or, if the restricted stock units are granted in lieu of an annual cash retainer, on the payment date selected by the director that is at least two years after the grant date. The estimated fair value of restricted stock awards is recognized on a straight-line basis over the vesting period. Restricted stock unit activity is as follows: Number of Shares Weighted Average Grant Date Fair Value Restricted stock units outstanding at June 30, 2015 262,943 $ 12.62 Granted 47,586 $ 22.27 Converted to common stock (5,713 ) $ 22.18 Restricted stock units outstanding at June 30, 2016 304,816 $ 13.95 Granted 54,064 $ 21.21 Forfeited (2,974 ) $ 21.01 Converted to common stock (6,476 ) $ 29.34 Restricted stock units outstanding at June 30, 2017 349,430 $ 14.73 Granted 28,364 $ 31.02 Converted to common stock (41,925 ) $ 16.07 Restricted stock units outstanding at June 30, 2018 335,869 $ 15.94 Stock-Based Compensation Expense The following amounts were recognized as stock-based compensation expense in the consolidated statements of operations: Year Ended June 30, 2018 Restricted Stock Awards Employee Stock Purchase Plan Restricted Stock Units Total Cost of goods sold $ 207 $ 68 $ — $ 275 Selling, general and administrative 7,462 848 750 9,060 Research and development 817 150 — 967 Total stock-based compensation expense $ 8,486 $ 1,066 $ 750 $ 10,302 Year Ended June 30, 2017 Restricted Stock Awards Employee Stock Purchase Plan Restricted Stock Units Total Cost of goods sold $ 588 $ 101 $ — $ 689 Selling, general and administrative 6,568 1,065 1,024 8,657 Research and development 879 129 — 1,008 Total stock-based compensation expense $ 8,035 $ 1,295 $ 1,024 $ 10,354 Year Ended June 30, 2016 Restricted Stock Awards Employee Stock Purchase Plan Restricted Stock Units Total Cost of goods sold $ 679 $ 115 $ — $ 794 Selling, general and administrative 8,215 1,167 1,000 10,382 Research and development 1,681 120 — 1,801 Total stock-based compensation expense $ 10,575 $ 1,402 $ 1,000 $ 12,977 Shares Available for Grant The following summarizes shares available for grant under the 2017 Plan: Reserved 3,607,523 Transferred from 2014 Plan (1,057,523 ) Granted (81,060 ) Forfeited or cancelled 95,525 Shares available for grant at June 30, 2018 2,564,465

Employee Stock Purchase Plan

Employee Stock Purchase Plan	12 Months Ended
	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Stock Purchase Plan	6. Employee Stock Purchase Plan The Company maintains an employee stock purchase plan that was approved by the Company’s stockholders in November 2015 (“2015 ESPP”) and replaced the previous employee stock purchase plan that expired on May 31, 2016. The 2015 ESPP provides eligible employees the opportunity to acquire common stock in accordance with Section 423 of the Internal Revenue Code of 1986. Stock can be purchased each six -month period per year (twice per year). The purchase price is equal to 85% of the lower of the price at the beginning or the end of the respective period. Employees purchased 158,939 shares at an average price of $20.40 per share during the year ended June 30, 2018 . Shares reserved under the 2015 ESPP at June 30, 2018 totaled 1,685,431 .

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes The components of the Company’s overall deferred tax assets and liabilities are as follows: June 30, 2018 2017 Deferred tax assets Stock-based compensation $ 2,505 $ 5,107 Deferred revenue 2,351 — Accrued expenses 970 1,650 Inventories 305 433 Compensation accruals 133 261 Depreciation and amortization 320 409 Other 397 1,019 Research and development credit carryforwards 5,048 4,650 Net operating loss carryforwards 64,101 87,502 Total deferred tax assets 76,130 101,031 Valuation allowance (76,130 ) (101,031 ) Net deferred tax assets $ — $ — On December 22, 2017, the United States enacted tax reform legislation commonly known as the Tax Cuts and Jobs Act (the “Act”), resulting in significant modifications to existing law. Accounting for the income tax effects of the Act which impact our tax provision has been completed as of the current year and included in the Company’s financial statements as of June 30, 2018. As a result of the Act, the Company remeasured deferred tax assets and liabilities from 34% to 21%, but given the Company is in a full valuation allowance position, there was no tax expense impact. The Company has established valuation allowances to fully offset its deferred tax assets due to the uncertainty about the Company’s ability to generate the future taxable income necessary to realize these deferred assets, particularly in light of the Company’s historical losses. The future use of net operating loss carryforwards is dependent on the Company attaining profitable operations, and may be limited in any one year under Internal Revenue Code Section 382 due to significant ownership changes, as defined under such Section, as a result of the Company’s equity financings. A summary of the valuation allowances are as follows: Balances at June 30, 2015 $ 84,319 Additions 16,898 Balance at June 30, 2016 101,217 Reductions (186 ) Balance at June 30, 2017 101,031 Reductions (24,901 ) Balance at June 30, 2018 $ 76,130 As of June 30, 2018 and 2017 , the Company had federal tax NOL carryforwards of approximately $275,030 and $287,598 , respectively. These NOL carryforwards are available to offset taxable income through 2037. The Company also had various state NOL carryforwards available to offset future state taxable income. These state NOL carryforwards typically have the same expirations as the Company’s federal tax NOL carryforwards. As of June 30, 2018 and 2017 , the Company had approximately $4,244 and $4,137 of federal research and development credit carryforwards, respectively. As of June 30, 2018 and 2017 , the Company had approximately $1,560 and $ 1,729 of state research and development credit carryforwards. The federal and state research and development credit carryforwards will expire through fiscal 2037 and 2032, respectively. As required by FASB ASC Topic 740, “Income Taxes,” the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recorded a liability relating to unrecognized tax benefits of $597 and $570 at June 30, 2018 and 2017 , respectively. Due to the Company having a full valuation allowance, this liability has been netted against the deferred tax asset. The Company recognizes interest and penalties related to uncertain tax provisions as part of the provision for income taxes. The Company has not currently reserved for any interest or penalties for such reserves due to the Company being in an NOL position. The Company does not expect to recognize any benefits from the unrecognized tax benefits within the next twelve months. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Balances at June 30, 2015 $ 494 Increases related to prior year tax positions 10 Increases related to current year tax positions 41 Balances at June 30, 2016 545 Decreases related to prior year tax positions (8 ) Increases related to current year tax positions 33 Balance at June 30, 2017 570 Decreases related to prior year tax positions (3 ) Increases related to current year tax positions 30 Balance at June 30, 2018 $ 597 The Company is subject to income taxes in the U.S. federal jurisdiction and various state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The Company is potentially subject to income tax examinations by tax authorities for the tax years ended June 30, 2018, 2017, 2016, and 2015. The Company is not currently under examination by any taxing jurisdiction.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Operating Leases The Company leases manufacturing space, equipment and apartments under lease agreements that expire at various dates through March 2020 . Rental expenses were $652 , $656 , and $1,049 , for the years ended June 30, 2018 , 2017 , and 2016 , respectively. In March 2017, the Company sold the Facility and began leasing the Facility. Future minimum lease payments under the agreements as of June 30, 2018 are as follows: 2019 $ 510 2020 376 2021 20 2022 — 2023 — Thereafter — $ 906 Other Matters In the ordinary conduct of business, the Company is subject to various lawsuits and claims covering a wide range of matters including, but not limited to, employment claims and commercial disputes. While the outcome of these matters is uncertain, the Company does not believe there are any significant matters as of June 30, 2018 that are probable or estimable, for which the outcome is reasonably possible of having a material adverse impact on its consolidated balance sheets or statements of operations.

Employee Benefits

Employee Benefits	12 Months Ended
	Jun. 30, 2018
Retirement Benefits [Abstract]
Employee Benefits	9. Employee Benefits The Company offers a 401(k) plan to its employees. Eligible employees may authorize up to $19 of their annual compensation as a contribution to the plan, subject to Internal Revenue Service limitations. The plan also allows eligible employees over 50 years old to contribute an additional $6 subject to Internal Revenue Service limitations. All employees must be at least 21 years of age to participate in the plan. The Company did not provide any employer matching contributions for the years ended June 30, 2018 , 2017 , and 2016 . The Company offers certain members of management and highly compensated employees the opportunity to defer up to 100% of their base salary (after 401(k), payroll tax and other deductions), performance bonus and discretionary bonus and elect to receive the deferred compensation at a fixed future date of participant’s choosing. Each participant may, at the time of his or her deferral election, choose to allocate the deferred compensation into investment alternatives set by the Human Resources and Compensation Committee. The amount payable to each participant under the plan will change in value based upon the investment selected by that participant and is classified as current or long-term on the Company’s balance sheet based on the disbursement elections made by the participants. As of June 30, 2018 , $149 of the amount is included in accrued expenses and $395 is included in other liabilities on the consolidated balance sheet.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Earnings Per Share	10. Earnings Per Share The following table presents a reconciliation of the numerators and denominators used in the basic and diluted earnings per common share computations (in thousands except share and per share amounts): Year Ended June 30, 2018 2017 2016 Numerator Net income (loss) $ 1,712 $ (1,792 ) $ (56,024 ) Income allocated to participating securities (19 ) — — Net income (loss) available to common stockholders $ 1,693 $ (1,792 ) $ (56,024 ) Denominator Weighted average common shares outstanding — basic 33,145,140 32,373,709 32,537,621 Effect of dilutive stock options (1) 15,039 — — Effect of dilutive restricted stock units (2) 335,869 — — Effect of performance-based restricted stock awards (3) 118,212 — — Weighted average common shares outstanding — diluted 33,614,260 32,373,709 32,537,621 Earnings per common share — basic $ 0.05 $ (0.06 ) $ (1.72 ) Earnings per common share — diluted $ 0.05 $ (0.06 ) $ (1.72 ) (1) At June 30, 2018 , 2017 , and 2016 ; 22,321 , 78,201 , and 606,879 stock options, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these options has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. (2) At June 30, 2018 , 2017 , and 2016 ; 335,869 , 349,430 and 304,816 additional shares of common stock, respectively, were issuable upon the settlement of outstanding restricted stock units. The effect of the shares that would be issued upon settlement of these restricted stock units has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. (3) At June 30, 2018 and 2017 , 531,178 and 318,584 , respectively, of performance-based restricted stock awards were outstanding. The effect of the shares that would be issued upon vesting of these awards has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. Unvested time-based restricted stock awards that contain nonforfeitable rights to dividends are participating securities and included in the computation of earnings per share pursuant to the two-class method. Under this method, earnings attributable to the Company are allocated between common stockholders and the participating awards, as if the awards were a second class of stock. During periods of net income, the calculation of earnings per share excludes the income attributable to participating securities in the numerator and the dilutive impact of these securities from the denominator. In the event of a net loss, undistributed earnings are not allocated to participating securities and the denominator excludes the dilutive impact of these securities as they do not share in the losses of the Company. During the year ended June 30, 2018 , undistributed earnings allocated to participating securities were based on 382,476 unvested time-based restricted stock awards.

Quarterly Data (Unaudited)

Quarterly Data (Unaudited)	12 Months Ended
	Jun. 30, 2018
Quarterly Financial Information Disclosure [Abstract]
Quarterly Data (Unaudited)	11. Quarterly Data (Unaudited) The following table sets forth the Company’s unaudited quarterly summary consolidated statements of operations in each of the quarters for the years ended June 30, 2018 and 2017 . The information for each of these quarters is unaudited and has been prepared on the same basis as the consolidated financial statements. This data should be read in conjunction with the consolidated financial statements and related notes. These operating results may not be indicative of results to be expected for any future period (amounts in thousands, except per share data). 2018 Q1 Q2 Q3 Q4 Total Net revenue $ 49,676 $ 52,628 $ 55,587 $ 59,152 $ 217,043 Gross profit $ 40,474 $ 43,129 $ 45,618 $ 48,338 $ 177,559 Net income (loss) $ (1,977 ) $ (413 ) $ 365 $ 3,737 $ 1,712 Earnings per common share - basic (1) $ (0.06 ) $ (0.01 ) $ 0.01 $ 0.11 $ 0.05 Earnings per common share - diluted (1) $ (0.06 ) $ (0.01 ) $ 0.01 $ 0.11 $ 0.05 2017 Q1 Q2 Q3 Q4 Total Net revenue $ 49,800 $ 50,043 $ 52,144 $ 52,919 $ 204,906 Gross profit $ 40,334 $ 40,880 $ 41,005 $ 43,246 $ 165,465 Net income (loss) $ (1,858 ) $ 1,043 $ (1,749 ) $ 772 $ (1,792 ) Earnings per common share - basic (1) $ (0.06 ) $ 0.03 $ (0.05 ) $ 0.02 $ (0.06 ) Earnings per common share - diluted (1) $ (0.06 ) $ 0.03 $ (0.05 ) $ 0.02 $ (0.06 ) (1) The summation of quarterly per share data may not equate to the calculation for the full fiscal year as quarterly calculations are performed on a discrete basis.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Company Description	Company Description Cardiovascular Systems, Inc. (the “Company”), based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The Company’s Orbital Atherectomy Systems (“OAS”) treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.
Principles of Consolidation	Principles of Consolidation The consolidated balance sheets and statements of operations, comprehensive loss, changes in stockholders’ equity, and cash flows include the accounts of the Company and its wholly-owned subsidiary, after elimination of all intercompany transactions and accounts.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all money market funds and other investments purchased with an original maturity of three months or less to be cash and cash equivalents.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the general standard being net 30 days. Collateral or any other security to support payment of these receivables generally is not required. The Company maintains an allowance for doubtful accounts, which is an estimate regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay. Provisions for the allowance for doubtful accounts attributed to bad debt are recorded in general and administrative expenses. The following table shows the allowance for doubtful accounts activity: Amount Balances at June 30, 2015 $ 1,437 Provision for doubtful accounts 375 Write-offs (1,100 ) Balance at June 30, 2016 712 Provision for doubtful accounts 465 Write-offs (313 ) Balance at June 30, 2017 864 Provision for doubtful accounts 125 Write-offs (189 ) Balance at June 30, 2018 $ 800
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out method of valuation. The establishment of inventory allowances for excess and obsolete inventories is based on estimated exposure on specific inventory items. The Company writes down its inventories as it becomes aware of any situation where the carrying amount exceeds the estimated realizable value based on assumptions about future demands and market conditions.
Property and Equipment	Property and Equipment Property and equipment is carried at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over estimated useful lives of 40 years for the building; five to seven years for production equipment and furniture and fixtures; three years for computer equipment and software; and the shorter of their estimated useful lives or the lease term for leasehold improvements. Expenditures for maintenance and repairs and minor renewals and betterments that do not extend or improve the life of the respective assets are expensed as incurred. All other expenditures for renewals and betterments are capitalized. The assets and related depreciation accounts are adjusted for property retirements and disposals with the resulting gains or losses included in the consolidated statement of operations.
Patents	Patents The capitalized costs incurred to obtain patents are amortized using the straight-line method over their remaining estimated lives. Patent amortization begins at the time of patent application approval, and does not exceed 20 years. The recoverability of capitalized patent costs is dependent upon the Company’s ability to derive revenue-producing products from such patents or the ultimate sale or licensing of such patent rights. Patent recoverability is regularly reviewed and any patents that are abandoned are written off at the time of abandonment.
Long-Lived Assets	Long-Lived Assets The Company regularly evaluates the carrying value of long-lived assets for events or changes in circumstances that indicate that the carrying amount may not be recoverable or that the remaining estimated useful life should be changed. An impairment loss is recognized when the carrying amount of an asset exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. The amount of the impairment loss to be recorded, if any, is calculated by the excess of the asset’s carrying value over its fair value.
Operating Leases	Operating Leases The Company leases its Texas manufacturing facilities under an operating lease agreement. The lease contains rent escalation clauses for which the lease expense is recognized on a straight-line basis over the lease term. Rent expense that is recognized but not yet paid is included in other liabilities on the consolidated balance sheets.
Financing Obligation	Financing Obligation In March 2017, the Company entered into an agreement to lease its Minnesota facility. The lease agreement has an initial term of fifteen years, with four consecutive renewal options of five years each at the Company's option. As the lease terms resulted in a capital lease classification, the Company accounted for the sale and leaseback of its Minnesota facility as a financing transaction where the assets remain on the Company's balance sheet and a financing obligation was recorded for $20,944. As lease payments are made, they will be allocated between interest expense and a reduction of the financing obligation, resulting in a value of the financing obligation that is equivalent to the net book value of the assets at the end of the lease term. At the end of the lease (including any renewal option terms), the Company will remove the assets and financing obligation from its balance sheet.
Revenue Recognition	Revenue Recognition The Company sells the majority of its products via direct shipment to hospitals or clinics. The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the sales price is fixed or determinable; and collectability is reasonably assured. Revenue recognition may occur upon shipment or upon delivery to the customer site, based on the contract terms. The Company records estimated sales returns, discounts and rebates as a reduction of net sales. Deferred revenue associated with the upfront payment received under the Company’s distribution agreement with Medikit is recognized in relation to the estimated future sales under the agreement. The short term portion represents the expected amount of deferred revenue that will be recognized over the next year. The estimate of future sales under contract will continue to be assessed and adjusted accordingly. Costs related to products delivered are recognized in the period the revenue is recognized. Cost of goods sold consists primarily of raw materials, direct labor, and manufacturing overhead.
Deferred Revenue	Deferred Revenue In November 2016, the Company signed an exclusive distribution agreement with Medikit Co., Ltd. (“Medikit”) to sell its Coronary and Peripheral OAS in Japan. To secure exclusive distribution rights, Medikit made an upfront payment of $10,000 to the Company, which is refundable based on the occurrence of certain events during the term of the agreement. The Company has classified the payment as current or long-term based on its expectation of when revenue will be recognized and is re-evaluated on a quarterly basis. Medikit also provides advance payments for orders under the terms of the agreement, and, therefore, deferred revenue is recorded until products are accepted by Medikit.
Warranty Costs	Warranty Costs The Company provides its customers with the right to receive a replacement if a product is determined to be defective at the time of shipment. Warranty reserve provisions are estimated based on Company experience, volume, and expected warranty claims. Warranty reserve, provisions and claims were as follows: Amount Balances at June 30, 2015 $ 126 Provision 490 Claims (471 ) Balance at June 30, 2016 145 Provision 1,733 Claims (1,361 ) Balance at June 30, 2017 517 Provision 328 Claims (713 ) Balance at June 30, 2018 $ 132 Pump Recall In April 2017, the Company initiated a voluntary recall of one type of its saline infusion pumps that resulted in a reserve of approximately $1,535 incurred in fiscal 2017, relating to estimated costs of the recall.
Litigation and Contingent Liabilities	Litigation and Contingent Liabilities The Company and its operations from time to time are, and in the future may be, parties to or targets of lawsuits, claims, investigations, and proceedings, which are handled and defended in the ordinary course of business. The Company accrues a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When a single amount cannot be reasonably estimated but the cost can be estimated within a range, the Company accrues an amount based on management’s best estimate considering all facts and circumstances. The Company expenses legal costs, including those expected to be incurred in connection with a loss contingency, as incurred.
Medical Device Excise Tax	Medical Device Excise Tax The Patient Protection and Affordable Care Act of 2010 imposed a medical device excise tax on medical device manufacturers on their sales in the United States of certain devices, which was effective January 1, 2013. The excise tax is 2.3% of the taxable base and applied to a substantial majority of the Company’s sales. Effective January 1, 2016, the excise tax was suspended until the end of 2017, and in January 2018, another temporary two year suspension of the tax was passed, extending the suspension to December 31, 2019. The Company incurred $1,273 of expense related to the tax during the year ended June 30, 2016.
Income Taxes	Income Taxes Deferred income taxes are recorded to reflect the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts based on enacted tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Developing a provision for income taxes, including the effective tax rate and the analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets. The Company’s judgment and tax strategies are subject to audit by various taxing authorities. Accounting guidance requires that accounting for uncertainty in income taxes is recognized in the financial statements. The guidance provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. The guidance also provides rules on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
Research and Development Expenses	Research and Development Expenses Research and development expenses include costs associated with the design, development, testing, enhancement and regulatory approval of the Company’s products. Research and development expenses include employee compensation (including stock-based compensation), supplies and materials, consulting expenses, patent amortization, travel and facilities overhead. The Company also incurs significant expenses to operate clinical trials, including trial design, third-party fees, clinical site reimbursement, data management and travel expenses. Research and development expenses are expensed as incurred. Expenses associated with patent applications are capitalized and amortized using the straight-line method over their remaining estimated lives. Patent amortization begins at the time of patent application approval, and does not exceed 20 years .
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains its cash balances primarily with one financial institution. These balances exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy and that credit risk related to accounts receivable is limited due to a large customer base.
Marketable Securities	Marketable Securities The Company’s marketable securities consist solely of available-for-sale securities and were valued in accordance with the fair value measurement guidance discussed below. Available-for-sale securities are carried at fair value with unrealized gains and losses reported as a component of stockholders’ equity as accumulated other comprehensive income (loss), net of tax. Realized gains and losses, if any, are calculated on the specific identification method and are included in interest and other, net in the consolidated statements of operations. Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported in equity as accumulated other comprehensive income (loss).
Cost Method Investments	Cost Method Investments When the Company controls less than 20% of the decision-making ability over the operations of the investee, the investment is accounted for at cost. Cost method investments are reviewed quarterly for any events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. When the fair value declines below the cost, an impairment loss is recognized unless it is considered temporary. Impairment is considered to be other than temporary if the length of time it will take for the investment’s value to exceed its cost is greater than the Company’s intent and ability to hold the investment.
Fair Value Measurements	Fair Value Measurements Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows: Level 1 Inputs — quoted prices in active markets for identical assets and liabilities Level 2 Inputs — observable inputs other than quoted prices in active markets for identical assets and liabilities Level 3 Inputs — unobservable inputs As of June 30, 2018 , the Company believes that the carrying amounts of its other financial instruments, including accounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4 for additional information.
Use of Estimates	Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and these differences could be material.
Stock-Based Compensation	Stock-Based Compensation The Company has stock-based compensation plans, which include stock options, nonvested share awards, and an employee stock purchase plan. Fair value of option awards is determined using option-pricing models, fair value of nonvested share awards with market conditions is determined using the Monte Carlo simulation, and fair value of nonvested share awards that vest based upon performance or service conditions is determined by the closing market price of the Company’s stock on the date of grant. Stock-based compensation expense is recognized ratably over the requisite service period for the awards expected to vest.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The Company has completed an adoption plan, which included a review of customer contracts, applying the five-step model of the new standard to the customer contracts and comparing the results to the Company’s current accounting. The Company has elected the modified retrospective method of adoption, which the Company anticipates will not result in a material adjustment to retained earnings. The Company’s revenue recognition will remain largely unchanged given the majority of the Company’s revenue arrangements consist of a single performance obligation that will be recognized at a point in time when control passes to the customer. As a result, the Company does not anticipate a material impact on the amount and timing of revenue recognized in the Company’s consolidated financial statements. The Company is also implementing new internal controls around the judgments needed to address risks associated with applying the five-step model, which includes identifying performance obligations and judgments made related to variable consideration. Effective July 1, 2018, the Company will be revising its revenue recognition accounting policy and disclosures to reflect the requirements of the amended revenue recognition guidance. The Company will continue to monitor any modifications or interpretations communicated by the FASB that may impact any of its final assessments related to the guidance. In January 2016, the FASB issued ASU 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities,” which revises the accounting requirements related to the classification and measurement of investments in equity securities and the presentation of certain fair value changes for financial liabilities measured at fair value. The update also changes certain disclosure requirements associated with the fair value of financial instruments. These changes will require an entity to measure, at fair value, investments in equity securities and recognize the changes in fair value within net income. ASU 2016-01 will be applied on a modified retrospective basis to all outstanding instruments, with an adjustment recorded to opening retained earnings as of the beginning of the first period in which the guidance becomes effective. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. The guidance is effective for the Company on July 1, 2018. The Company does not anticipate a material impact on its financial statements upon adoption. In February 2016, the FASB issued ASU 2016-02, “Leases.” The guidance requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, and should be applied using a modified retrospective approach. Early adoption is permitted. The guidance is effective for the Company on July 1, 2019. The Company is currently evaluating the timing, method of adoption and impact of the new lease guidance on its financial statements. In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which revises guidance for the accounting for credit losses on financial instruments within its scope. The new standard introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new approach to estimating credit losses (referred to as the current expected credit losses model) applies to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases and off-balance-sheet credit exposures. ASU 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted and should be applied as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The guidance is effective for the Company on July 1, 2020. The Company does not anticipate a material impact on its financial statements upon adoption. In May 2017, the FASB issued ASU 2017-09, “Scope of Modification Accounting” which clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. The guidance is effective for annual periods, and interim periods within those annual periods beginning after December 15, 2017, with early adoption permitted. The Company does not anticipate a material impact on its financial statements upon adoption.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Allowance for doubtful accounts	Amount Balances at June 30, 2015 $ 1,437 Provision for doubtful accounts 375 Write-offs (1,100 ) Balance at June 30, 2016 712 Provision for doubtful accounts 465 Write-offs (313 ) Balance at June 30, 2017 864 Provision for doubtful accounts 125 Write-offs (189 ) Balance at June 30, 2018 $ 800
Warranty reserve, provisions and claims	Amount Balances at June 30, 2015 $ 126 Provision 490 Claims (471 ) Balance at June 30, 2016 145 Provision 1,733 Claims (1,361 ) Balance at June 30, 2017 517 Provision 328 Claims (713 ) Balance at June 30, 2018 $ 132

Selected Consolidated Financi22

Selected Consolidated Financial Statement Information (Tables)	12 Months Ended
	Jun. 30, 2018
Quarterly Financial Information Disclosure [Abstract]
Accounts receivable	June 30, 2018 2017 Accounts receivable $ 32,025 $ 29,336 Less: Allowance for doubtful accounts (800 ) (864 ) Accounts receivable, net $ 31,225 $ 28,472
Inventories	June 30, 2018 2017 Raw materials $ 6,820 $ 7,898 Work in process 1,315 1,221 Finished goods 8,470 7,778 Inventories $ 16,605 $ 16,897
Property and equipment	June 30, 2018 2017 Land $ 500 $ 500 Building 22,420 22,420 Equipment 16,510 16,502 Furniture 2,709 2,709 Leasehold improvements 438 86 Construction in progress 1,110 421 43,687 42,638 Less: Accumulated depreciation (15,943 ) (12,942 ) Total Property and equipment, net $ 27,744 $ 29,696
Patents, net	June 30, 2018 2017 Patents $ 6,435 $ 6,056 Less: Accumulated amortization (1,204 ) (1,000 ) Total Patents, net $ 5,231 $ 5,056
Patent amortization schedule	As of June 30, 2018 , future estimated amortization of patents is as follows: 2019 $ 199 2020 193 2021 191 2022 181 2023 174 Thereafter 4,293 $ 5,231
Accrued expenses	June 30, 2018 2017 Commissions $ 7,234 $ 8,217 Salaries and bonus 6,624 8,247 Accrued vacation 3,557 3,436 Accrued excise, sales and other taxes 3,522 3,497 Legal settlement 1,847 1,814 Clinical studies 1,422 657 Accrued litigation — 2,600 Other accrued expenses 1,570 1,768 Total Accrued expenses $ 25,776 $ 30,236
Non-current other liabilities	June 30, 2018 2017 Legal settlement $ 467 $ 2,314 Deferred compensation 395 519 Deferred grant incentive 460 473 Other liabilities 90 173 Total Other liabilities $ 1,412 $ 3,479

Debt (Tables)

Debt (Tables)	12 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Schedule of future minimum lease payments	2019 $ 1,699 2020 1,750 2021 1,803 2022 1,857 2023 1,913 Thereafter 19,375 $ 28,397

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Jun. 30, 2018
Compensation Related Costs [Abstract]
Available-for-sale marketable securities at fair value on recurring basis	Fair Value Measurements as of June 30, 2018 Using Inputs Considered as Fair Value Level 1 Level 2 Level 3 Mutual funds $ 544 199 345 $ — Total marketable securities $ 544 199 345 $ — Fair Value Measurements as of June 30, 2017 Using Inputs Considered as Fair Value Level 1 Level 2 Level 3 Mutual funds $ 704 281 423 $ — Total marketable securities $ 704 281 423 $ —

Stock Options and Restricted 25

Stock Options and Restricted Stock Awards (Tables)	12 Months Ended
	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock option activity	Number of Options Weighted Average Exercise Price Options outstanding at June 30, 2015 699,872 $ 10.32 Exercised (87,817 ) $ 11.46 Forfeited or expired (5,176 ) $ 12.37 Options outstanding at June 30, 2016 606,879 $ 10.14 Exercised (519,297 ) $ 10.33 Expired (9,381 ) $ 8.83 Options outstanding at June 30, 2017 78,201 $ 9.07 Exercised (55,880 ) $ 9.20 Options outstanding at June 30, 2018 22,321 $ 8.75
Restricted stock award activity	Number of Shares Weighted Average Grant Date Fair Value Outstanding at June 30, 2015 843,094 $ 25.16 Granted 522,415 $ 19.30 Forfeited (230,710 ) $ 24.83 Vested (487,226 ) $ 22.27 Outstanding at June 30, 2016 647,573 $ 23.24 Granted 258,346 $ 21.80 Forfeited (103,140 ) $ 22.11 Vested (316,195 ) $ 24.21 Outstanding at June 30, 2017 486,584 $ 21.26 Granted 290,856 $ 27.93 Forfeited (68,499 ) $ 22.76 Vested (253,725 ) $ 22.87 Outstanding at June 30, 2018 455,216 $ 24.77
Aggregate maximum performance-based restricted stock awards granted	Performance Measurement 2018 2017 2016 Total shareholder return 278,889 336,826 156,509 Annual revenue growth N/A N/A 156,509
Performance-based restricted stock award activity	Number of Weighted Average Outstanding at June 30, 2015 152,224 $ 22.03 Granted 313,018 $ 16.67 Forfeited (52,680 ) $ 28.64 Vested (102,451 ) $ 25.58 Outstanding at June 30, 2016 310,111 $ 16.67 Granted 336,826 $ 11.97 Forfeited (328,353 ) $ 16.41 Outstanding at June 30, 2017 318,584 $ 11.97 Granted 278,889 $ 13.63 Forfeited (66,295 ) $ 13.17 Outstanding at June 30, 2018 531,178 $ 12.69
Restricted stock unit activity	Number of Shares Weighted Average Grant Date Fair Value Restricted stock units outstanding at June 30, 2015 262,943 $ 12.62 Granted 47,586 $ 22.27 Converted to common stock (5,713 ) $ 22.18 Restricted stock units outstanding at June 30, 2016 304,816 $ 13.95 Granted 54,064 $ 21.21 Forfeited (2,974 ) $ 21.01 Converted to common stock (6,476 ) $ 29.34 Restricted stock units outstanding at June 30, 2017 349,430 $ 14.73 Granted 28,364 $ 31.02 Converted to common stock (41,925 ) $ 16.07 Restricted stock units outstanding at June 30, 2018 335,869 $ 15.94
Stock-based compensation expense	Year Ended June 30, 2018 Restricted Stock Awards Employee Stock Purchase Plan Restricted Stock Units Total Cost of goods sold $ 207 $ 68 $ — $ 275 Selling, general and administrative 7,462 848 750 9,060 Research and development 817 150 — 967 Total stock-based compensation expense $ 8,486 $ 1,066 $ 750 $ 10,302 Year Ended June 30, 2017 Restricted Stock Awards Employee Stock Purchase Plan Restricted Stock Units Total Cost of goods sold $ 588 $ 101 $ — $ 689 Selling, general and administrative 6,568 1,065 1,024 8,657 Research and development 879 129 — 1,008 Total stock-based compensation expense $ 8,035 $ 1,295 $ 1,024 $ 10,354 Year Ended June 30, 2016 Restricted Stock Awards Employee Stock Purchase Plan Restricted Stock Units Total Cost of goods sold $ 679 $ 115 $ — $ 794 Selling, general and administrative 8,215 1,167 1,000 10,382 Research and development 1,681 120 — 1,801 Total stock-based compensation expense $ 10,575 $ 1,402 $ 1,000 $ 12,977
Shares available for grant	Reserved 3,607,523 Transferred from 2014 Plan (1,057,523 ) Granted (81,060 ) Forfeited or cancelled 95,525 Shares available for grant at June 30, 2018 2,564,465

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Deferred tax assets and liabilities	June 30, 2018 2017 Deferred tax assets Stock-based compensation $ 2,505 $ 5,107 Deferred revenue 2,351 — Accrued expenses 970 1,650 Inventories 305 433 Compensation accruals 133 261 Depreciation and amortization 320 409 Other 397 1,019 Research and development credit carryforwards 5,048 4,650 Net operating loss carryforwards 64,101 87,502 Total deferred tax assets 76,130 101,031 Valuation allowance (76,130 ) (101,031 ) Net deferred tax assets $ — $ —
Summary of valuation allowances	Balances at June 30, 2015 $ 84,319 Additions 16,898 Balance at June 30, 2016 101,217 Reductions (186 ) Balance at June 30, 2017 101,031 Reductions (24,901 ) Balance at June 30, 2018 $ 76,130
Reconciliation of beginning and ending amount of unrecognized tax benefits	Balances at June 30, 2015 $ 494 Increases related to prior year tax positions 10 Increases related to current year tax positions 41 Balances at June 30, 2016 545 Decreases related to prior year tax positions (8 ) Increases related to current year tax positions 33 Balance at June 30, 2017 570 Decreases related to prior year tax positions (3 ) Increases related to current year tax positions 30 Balance at June 30, 2018 $ 597

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Future minimum lease payments	2019 $ 510 2020 376 2021 20 2022 — 2023 — Thereafter — $ 906

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Reconciliation of the numerators and denominators used in the basic and diluted earnings per common share computations	Year Ended June 30, 2018 2017 2016 Numerator Net income (loss) $ 1,712 $ (1,792 ) $ (56,024 ) Income allocated to participating securities (19 ) — — Net income (loss) available to common stockholders $ 1,693 $ (1,792 ) $ (56,024 ) Denominator Weighted average common shares outstanding — basic 33,145,140 32,373,709 32,537,621 Effect of dilutive stock options (1) 15,039 — — Effect of dilutive restricted stock units (2) 335,869 — — Effect of performance-based restricted stock awards (3) 118,212 — — Weighted average common shares outstanding — diluted 33,614,260 32,373,709 32,537,621 Earnings per common share — basic $ 0.05 $ (0.06 ) $ (1.72 ) Earnings per common share — diluted $ 0.05 $ (0.06 ) $ (1.72 ) (1) At June 30, 2018 , 2017 , and 2016 ; 22,321 , 78,201 , and 606,879 stock options, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these options has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. (2) At June 30, 2018 , 2017 , and 2016 ; 335,869 , 349,430 and 304,816 additional shares of common stock, respectively, were issuable upon the settlement of outstanding restricted stock units. The effect of the shares that would be issued upon settlement of these restricted stock units has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. (3) At June 30, 2018 and 2017 , 531,178 and 318,584 , respectively, of performance-based restricted stock awards were outstanding. The effect of the shares that would be issued upon vesting of these awards has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Quarterly Data (Unaudited) (Tab

Quarterly Data (Unaudited) (Tables)	12 Months Ended
	Jun. 30, 2018
Quarterly Financial Information Disclosure [Abstract]
Schedule of quarterly financial information	2018 Q1 Q2 Q3 Q4 Total Net revenue $ 49,676 $ 52,628 $ 55,587 $ 59,152 $ 217,043 Gross profit $ 40,474 $ 43,129 $ 45,618 $ 48,338 $ 177,559 Net income (loss) $ (1,977 ) $ (413 ) $ 365 $ 3,737 $ 1,712 Earnings per common share - basic (1) $ (0.06 ) $ (0.01 ) $ 0.01 $ 0.11 $ 0.05 Earnings per common share - diluted (1) $ (0.06 ) $ (0.01 ) $ 0.01 $ 0.11 $ 0.05 2017 Q1 Q2 Q3 Q4 Total Net revenue $ 49,800 $ 50,043 $ 52,144 $ 52,919 $ 204,906 Gross profit $ 40,334 $ 40,880 $ 41,005 $ 43,246 $ 165,465 Net income (loss) $ (1,858 ) $ 1,043 $ (1,749 ) $ 772 $ (1,792 ) Earnings per common share - basic (1) $ (0.06 ) $ 0.03 $ (0.05 ) $ 0.02 $ (0.06 ) Earnings per common share - diluted (1) $ (0.06 ) $ 0.03 $ (0.05 ) $ 0.02 $ (0.06 ) (1) The summation of quarterly per share data may not equate to the calculation for the full fiscal year as quarterly calculations are performed on a discrete basis.

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details Textual) $ in Thousands	12 Months Ended
	Jun. 30, 2018financial_institution	Jun. 30, 2016USD ($)
Accounting Policies [Abstract]
Accounts receivable credit period	30 days
Property and Equipment and Patents [Line Items]
Medical Device Excise Tax, percentage	2.30%
Medical Device Excise Tax | $		$ 1,273
Number of financial institutions the company maintains its cash balances | financial_institution	1
Building
Property and Equipment and Patents [Line Items]
Property and equipment, estimated useful life	40 years
Computer Equipment
Property and Equipment and Patents [Line Items]
Property and equipment, estimated useful life	3 years
Minimum | Equipment
Property and Equipment and Patents [Line Items]
Property and equipment, estimated useful life	5 years
Maximum
Property and Equipment and Patents [Line Items]
Patent amortization tenure	20 years
Maximum | Equipment
Property and Equipment and Patents [Line Items]
Property and equipment, estimated useful life	7 years

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Allowance for Doubtful Accounts Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Allowance for doubtful accounts activity
Beginning balance	$ 864	$ 712	$ 1,437
Provision for doubtful accounts	125	465	375
Write-offs	(189)	(313)	(1,100)
Ending balance	$ 800	$ 864	$ 712

Summary of Significant Accoun32

Summary of Significant Accounting Policies (Warranty Reserve) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Warranty reserve, provisions and claims
Beginning balance	$ 517	$ 145	$ 126
Provision	328	1,733	490
Claims	(713)	(1,361)	(471)
Ending balance	$ 132	517	$ 145
Pump recall disclosures
Recall Expense, Inventory Reserve		$ 1,535

Selected Consolidated Financi33

Selected Consolidated Financial Statement Information (Accounts Receivable, Net) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Quarterly Financial Information Disclosure [Abstract]
Accounts receivable	$ 32,025	$ 29,336
Less: Allowance for doubtful accounts	(800)	(864)
Accounts receivable, net	$ 31,225	$ 28,472

Selected Consolidated Financi34

Selected Consolidated Financial Statement Information (Inventories) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Quarterly Financial Information Disclosure [Abstract]
Raw materials	$ 6,820	$ 7,898
Work in process	1,315	1,221
Finished goods	8,470	7,778
Inventories	$ 16,605	$ 16,897

Selected Consolidated Financi35

Selected Consolidated Financial Statement Information (Property and Equipment) (Details) - USD ($) $ in Thousands	Mar. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Property, Plant and Equipment [Line Items]
Total Property and equipment		$ 43,687	$ 42,638
Less: Accumulated depreciation		(15,943)	(12,942)
Total Property and equipment, net		27,744	29,696
Sale Agreement
Facility Purchase Price	$ 21,500
Net Proceeds on Sale of the Facility	20,944
Transaction Costs, Sale Leaseback	556
Gain (Loss) on Sale of Assets and Asset Impairment Charges	$ 158
Land
Property, Plant and Equipment [Line Items]
Total Property and equipment		500	500
Building
Property, Plant and Equipment [Line Items]
Total Property and equipment		22,420	22,420
Equipment
Property, Plant and Equipment [Line Items]
Total Property and equipment		16,510	16,502
Furniture
Property, Plant and Equipment [Line Items]
Total Property and equipment		2,709	2,709
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total Property and equipment		438	86
Construction in progress
Property, Plant and Equipment [Line Items]
Total Property and equipment		$ 1,110	$ 421

Selected Consolidated Financi36

Selected Consolidated Financial Statement Information (Patents, Net) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Quarterly Financial Information Disclosure [Abstract]
Patents	$ 6,435	$ 6,056
Less: Accumulated amortization	(1,204)	(1,000)
Total Patents	$ 5,231	$ 5,056

Selected Consolidated Financi37

Selected Consolidated Financial Statement Information (Estimated Amortization of Patents) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Estimated amortization of patents and patent licenses
2,019	$ 199
2,020	193
2,021	191
2,022	181
2,023	174
Thereafter	4,293
Total Patents	$ 5,231	$ 5,056

Selected Consolidated Financi38

Selected Consolidated Financial Statement Information (Accrued Expenses) (Details) $ in Thousands	Jun. 28, 2016USD ($)installment_paymentRate	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)
Accrued expenses
Commissions		$ 6,624	$ 8,217
Salaries and bonus		7,234	8,247
Accrued vacation		3,557	3,436
Accrued excise, sales and other taxes		3,522	3,497
Legal settlement		1,847	1,814
Clinical studies		1,422	657
Accrued litigation		0	2,600
Other accrued expenses		1,570	1,768
Total Accrued expenses		$ 25,776	$ 30,236
Legal settlement
Litigation Settlement, Amount Awarded to Other Party	$ 8,000
Payments for Legal Settlements	3,000
Settlement Payable in Installments	$ 5,000
Litigation Settlement Interest, Percentage | Rate	0.00%
Litigation Settlement, Number of Quarterly Installment Payment | installment_payment	11
Single payment threshold amount	$ 2,000

Selected Consolidated Financi39

Selected Consolidated Financial Statement Information (Restructuring Accrual) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Document Period End Date	Jun. 30, 2018
Restructuring charge	$ 0	$ 0	$ 2,364
Accrued Liabilities
Restructuring Reserve, Current	$ 22	$ 169

Selected Consolidated Financi40

Selected Consolidated Financial Statement Information (Other Liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Quarterly Financial Information Disclosure [Abstract]
Legal settlement	$ 467	$ 2,314
Deferred compensation	395	519
Deferred grant incentive	460	473
Other liabilities	90	173
Total Other liabilities	$ 1,412	$ 3,479

Debt (Revolving Credit Facility

Debt (Revolving Credit Facility) (Details) - Revolving Credit Facility [Member] - Silicon Valley Bank [Member] - USD ($)	Mar. 31, 2017	Jun. 30, 2018
Debt Instrument [Line Items]
Percentage of Eligible Accounts Receivable	85.00%
Maximum [Member]
Debt Instrument [Line Items]
Borrowings Available On A Formula Basis	$ 10,000,000
Prime Rate [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 40,000,000
Line of Credit Facility, Expiration Date	Mar. 31, 2020
Percent Reduction to Prime Interest Rate	0.25%
Percent of Eligible Inventory	50.00%
Maximum Eligible Inventory Value	$ 5,000,000
Early Termination Fee	1.00%
Covenant, Minimum Unused Availability	$ 10,000,000
Covenant, Adjusted EBITDA	$ 1,000,000
Interest Rate Increase For Noncompliance	5.00%
Line of Credit Facility, Commitment Fee Amount	$ 80,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.00%
Number of Days for Collateral Examination	90 days
Line of Credit Facility, Fair Value of Amount Outstanding		$ 0

Debt (Financing Obligation) (De

Debt (Financing Obligation) (Details) - Financing Obligation [Member] $ in Thousands	3 Months Ended
	Jun. 30, 2018USD ($)optionsRate
Capital Lease Obligations
Capital lease term of contract (in years)	15 years
Capital lease number of renewal options | options	4
Capital lease term of renewal (in years)	5 years
Annual base rent	$ 1,638
Annual interest rate escalations (as a percent) | Rate	3.00%
Effective interest rate (as a percent) | Rate	7.89%
Capital Leases, Future Payments
Capital Leases, Future Minimum Payments Due, Next Twelve Months	$ 1,699
Capital Leases, Future Minimum Payments Due in Two Years	1,750
Capital Leases, Future Minimum Payments Due in Three Years	1,803
Capital Leases, Future Minimum Payments Due in Four Years	1,857
Capital Leases, Future Minimum Payments Due in Five Years	1,913
Capital Leases, Future Minimum Payments Due Thereafter	19,375
Capital Leases, Future Minimum Payments Due	$ 28,397

Fair Value (Details)

Fair Value (Details) - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Purchases of available-for-sale securities	$ 0	$ 0	$ 37,000
Sale of available-for-sale securities	194,000	40,000
Other-than-temporary impairments	0	0
Interest and Other, Net
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Realized gain	34,000	$ 6,000
Accrued Expenses
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Deferred compensation payable, current	149,000
Other Liabilities
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Deferred compensation payable, current	$ 395,000

Fair Value (Investments) (Detai

Fair Value (Investments) (Details)	Jun. 30, 2018USD ($)
Investment [Line Items]
Cost Method Investments	$ 2,538

Fair Value (Available-for-sale

Fair Value (Available-for-sale Securities on Recurring Basis) (Details) - USD ($)	Jun. 30, 2018	Jun. 30, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	$ 0
Fair Value, Assets, Level 2 to Level 1 Transfers, Amount	0
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	544,000	$ 704,000
Recurring | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	544,000	704,000
Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	199,000	281,000
Recurring | Level 1 | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	199,000	281,000
Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	345,000	423,000
Recurring | Level 2 | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	345,000	423,000
Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	0	0
Recurring | Level 3 | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	0	$ 0
Other Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation payable, current	$ 395,000

Stock Options and Restricted 46

Stock Options and Restricted Stock Awards (Details) - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock approved	3,607,523
Vested options granted to employees after termination	90 days
Options granted	0	0	0
Aggregate intrinsic value for vested and outstanding options	$ 527,000	$ 1,811,000	$ 4,025,000
Total aggregate intrinsic value of options exercised	1,095,000	7,955,000	417,000
Cash received from option exercises	$ 514,000	$ 5,363,000	$ 1,006,000
Weighted-average contractual life of options outstanding	8 months
Forfeiture rate	15.20%	17.10%	17.00%
Total compensation cost for non-vested awards not yet recognized	$ 8,171,000
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of vested stocks	$ 5,803,000	$ 7,655,000	$ 10,851,000
Weighted-average period expected to recognize nonvested awards	1 year 7 months 5 days
Restricted Stock Awards | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Restricted Stock Awards | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of vested stocks	$ 0	$ 0	$ 2,621,000
Total compensation cost for non-vested awards not yet recognized	$ 2,791
Weighted-average period expected to recognize nonvested awards	1 year 7 months 5 days
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum period for payment on restricted stock unit following the six month anniversary date	30 days
Minimum period after grant date	2 years

Stock Options and Restricted 47

Stock Options and Restricted Stock Awards (Stock Option Activity) (Details) - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Number of Options
Beginning balance (in shares)	78,201	606,879	699,872
Exercised (in shares)	(55,880)	(519,297)	(87,817)
Forfeited or expired			$ (5,176)
Expired (in shares)		(9,381)
Ending balance (in shares)	22,321	78,201	606,879
Weighted Average Exercise Price
Beginning balance (in usd per share)	$ 9.07	$ 10.14	$ 10.32
Exercised (in usd per share)	9.20	10.33	11.46
Forfeited or expired (in usd per share)			12.37
Expired (in usd per share)		8.83
Ending balance (in usd per share)	$ 8.75	$ 9.07	$ 10.14

Stock Options and Restricted 48

Stock Options and Restricted Stock Awards (Restricted Stock) (Details) - Restricted Stock - $ / shares	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Number of Shares
Outstanding at beginning of period (in shares)	486,584	647,573	843,094
Granted (in shares)	290,856	258,346	522,415
Forfeited (in shares)	(68,499)	(103,140)	(230,710)
Vested (in shares)	(253,725)	(316,195)	(487,226)
Outstanding at end of period (in shares)	455,216	486,584	647,573
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (in usd per share)	$ 21.26	$ 23.24	$ 25.16
Forfeited (in usd per share)	22.76	22.11	24.83
Granted (in usd per share)	27.93	21.80	19.30
Vested (in usd per share)	22.87	24.21	22.27
Outstanding at end of period (in usd per share)	$ 24.77	$ 21.26	$ 23.24

Stock Options and Restricted 49

Stock Options and Restricted Stock Awards (Maximum Performance Shares Granted) (Details) - Performance Shares - shares	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance Measurement (in shares)	278,889	336,826	313,018
Total Shareholder Return
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance Measurement (in shares)	278,889	336,826	156,509
Annual Revenue Growth
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance Measurement (in shares)			156,509

Stock Options and Restricted 50

Stock Options and Restricted Stock Awards (Performance Based Restricted Stock Awards) (Details) - shares	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(66,295)	(328,353)	(52,680)
Vested (in shares)			102,451
Total Shareholder Return
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
TSR Performance Result			0.00%
Vested (in shares)			0

Stock Options and Restricted 51

Stock Options and Restricted Stock Awards (Performace-based Restricted Stock Award Activity) (Details) - Performance Shares - $ / shares	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Number of Shares
Outstanding at beginning of period (in shares)	318,584	310,111	152,224
Granted (in shares)	278,889	336,826	313,018
Vested (in shares)			(102,451)
Forfeited (in shares)	(66,295)	(328,353)	(52,680)
Outstanding at end of period (in shares)	531,178	318,584	310,111
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (in usd per share)	$ 11.97	$ 16.67	$ 22.03
Granted (in usd per share)	13.63	11.97	16.67
Vested (in usd per share)			25.58
Forfeited (in usd per share)	13.17	16.41	28.64
Outstanding at end of period (in usd per share)	$ 12.69	$ 11.97	$ 16.67

Stock Options and Restricted 52

Stock Options and Restricted Stock Awards (Restricted Stock Unit Activity) (Details) - Restricted Stock Units - $ / shares	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Number of Shares
Outstanding at beginning of period (in shares)	349,430	304,816	262,943
Granted (in shares)	28,364	54,064	47,586
Forfeited (in shares)		(2,974)
Converted to common stock (in shares)	(41,925)	(6,476)	(5,713)
Outstanding at end of period (in shares)	335,869	349,430	304,816
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (in usd per share)	$ 14.73	$ 13.95	$ 12.62
Granted (in usd per share)	31.02	21.21	22.27
Forfeited (in usd per share)		21.01
Converted to common stock	16.07	29.34	22.18
Outstanding at end of period (in usd per share)	$ 15.94	$ 14.73	$ 13.95

Stock Options and Restricted 53

Stock Options and Restricted Stock Awards (Stock-based Compensation Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 10,302	$ 10,354	$ 12,977
Restricted Stock Awards
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	8,486	8,035	10,575
Employee Stock Purchase Plan
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,066	1,295	1,402
Restricted Stock Units
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	750	1,024	1,000
Cost of goods sold
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	275	689	794
Cost of goods sold | Restricted Stock Awards
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	207	588	679
Cost of goods sold | Employee Stock Purchase Plan
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	68	101	115
Cost of goods sold | Restricted Stock Units
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	0	0	0
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	9,060	8,657	10,382
Selling, general and administrative | Restricted Stock Awards
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	7,462	6,568	8,215
Selling, general and administrative | Employee Stock Purchase Plan
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	848	1,065	1,167
Selling, general and administrative | Restricted Stock Units
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	750	1,024	1,000
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	967	1,008	1,801
Research and development | Restricted Stock Awards
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	817	879	1,681
Research and development | Employee Stock Purchase Plan
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	150	129	120
Research and development | Restricted Stock Units
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 0	$ 0	$ 0

Stock Options and Restricted 54

Stock Options and Restricted Stock Awards (Shares Available for Grant) (Details)	12 Months Ended
	Jun. 30, 2018shares
Shares available for grant
Granted (in shares)	(81,060)
Forfeited or cancelled (in shares)	95,525
Ending balance (in shares)	2,564,465
2014 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Transferred Available For Grant	1,057,523

Employee Stock Purchase Plan (D

Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan [Member]	12 Months Ended
	Jun. 30, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock purchase period	6 months
Purchase price of stock in percentage	85.00%
Number of shares purchased by employee	158,939
Average price of share purchased by employee | $ / shares	$ 20.40
Shares of common stock reserved under the ESPP	1,685,431

Income Taxes (Deferred Tax Asse

Income Taxes (Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Deferred tax assets
Stock-based compensation	$ 2,505	$ 5,107
Deferred Tax Assets, Deferred Income	2,351	0
Accrued expenses	970	1,650
Inventories	305	433
Compensation accruals	133	261
Depreciation and amortization	320	409
Other	397	1,019
Research and development credit carryforwards	5,048	4,650
Net operating loss carryforwards	64,101	87,502
Total deferred tax assets	76,130	101,031
Valuation allowance	(76,130)	(101,031)	$ (101,217)	$ (84,319)
Net deferred tax assets	$ 0	$ 0

Income Taxes (Valuation Allowan

Income Taxes (Valuation Allowance) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Summary of valuation allowances
Beginning balance	$ 101,031	$ 101,217	$ 84,319
Additions	(24,901)	(186)	16,898
Ending balance	$ 76,130	$ 101,031	$ 101,217

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Operating Loss Carryforwards [Line Items]
Liability relating to unrecognized tax benefits	$ 597	$ 570	$ 545	$ 494
Federal
Operating Loss Carryforwards [Line Items]
Tax NOL carryforwards	275,030	287,598
Research and development credit carryforwards	4,244	4,137
State
Operating Loss Carryforwards [Line Items]
Research and development credit carryforwards	$ 1,560	$ 1,729

Income Taxes (Unrecognized Tax

Income Taxes (Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Reconciliation of beginning and ending amount of unrecognized tax benefits
Beginning balance	$ 570	$ 545	$ 494
Decreases related to prior year tax positions			10
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions	(3)	(8)
Increases related to current year tax positions	(30)	(33)	(41)
Ending balance	$ 597	$ 570	$ 545

Commitments and Contingencies60

Commitments and Contingencies (Operating Leases) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Rental expenses	$ 652	$ 656	$ 1,049
Operating Leases, Future Minimum Payments Receivable [Abstract]
2,019	510
2,020	376
2,021	20
2,022	0
2,023	0
Thereafter	0
Total	$ 906

Employee Benefits (Details)

Employee Benefits (Details) - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Defined Benefit Plan Disclosure [Line Items]
Contribution by employee in plan	$ 19,000
Age of eligible employees for contribute additional amount	50 years
Additional contribution by employee in plan	$ 6,000
Minimum age for qualifying in 401(a) plan	21 years
Document Period End Date	Jun. 30, 2018
Employer matching contributions	$ 0	$ 0	$ 0
Other Liabilities
Defined Benefit Plan Disclosure [Line Items]
Deferred compensation payable, current	395,000
Accrued Expenses
Defined Benefit Plan Disclosure [Line Items]
Deferred compensation payable, current	$ 149,000

Earnings Per Share (Reconciliat

Earnings Per Share (Reconciliation of Numerators and Denominators) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Numerator
Net income (loss)	$ 3,737	$ 365	$ (413)	$ (1,977)	$ 772	$ (1,749)	$ 1,043	$ (1,858)	$ 1,712	$ (1,792)	$ (56,024)
Undistributed Earnings (Loss) Allocated to Participating Securities, Basic									(19)	0	0
Undistributed Earnings (Loss) Available to Common Shareholders, Basic									$ 1,693	$ (1,792)	$ (56,024)
Denominator
Weighted average common shares - basic (in shares)									33,145,140	32,373,709	32,537,621
Weighted average common shares outstanding - diluted (in shares)									33,614,260	32,373,709	32,537,621
Earnings per common share — basic	$ 0.11	$ 0.01	$ (0.01)	$ (0.06)	$ 0.02	$ (0.05)	$ 0.03	$ (0.06)	$ 0.05	$ (0.06)	$ (1.72)
Earnings per common share — diluted	$ 0.11	$ 0.01	$ (0.01)	$ (0.06)	$ 0.02	$ (0.05)	$ 0.03	$ (0.06)	$ 0.05	$ (0.06)	$ (1.72)
Stock Options
Denominator
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements									15,039	0	0
Restricted Stock Units
Denominator
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements									335,869	0	0
Performance Shares
Denominator
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements									118,212	0	0

Earnings Per Share (Details Tex

Earnings Per Share (Details Textual) - shares	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Document Period End Date	Jun. 30, 2018
Common stock, shares outstanding	33,360,032	32,792,497
Undistributed earnings allocation, number unvested time-based shares	382,476
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, shares outstanding	22,321	78,201	606,879
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, shares outstanding	335,869	349,430	304,816
Performance Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, shares outstanding	531,178	318,584

Quarterly Data (Unaudited) (Det

Quarterly Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Quarterly Financial Information Disclosure [Abstract]
Net revenues	$ 59,152	$ 55,587	$ 52,628	$ 49,676	$ 52,919	$ 52,144	$ 50,043	$ 49,800	$ 217,043	$ 204,906	$ 178,184
Gross profit	48,338	45,618	43,129	40,474	43,246	41,005	40,880	40,334	177,559	165,465	142,763
Net income (loss)	$ 3,737	$ 365	$ (413)	$ (1,977)	$ 772	$ (1,749)	$ 1,043	$ (1,858)	$ 1,712	$ (1,792)	$ (56,024)
Earnings per common share — basic	$ 0.11	$ 0.01	$ (0.01)	$ (0.06)	$ 0.02	$ (0.05)	$ 0.03	$ (0.06)	$ 0.05	$ (0.06)	$ (1.72)
Earnings per common share — diluted	$ 0.11	$ 0.01	$ (0.01)	$ (0.06)	$ 0.02	$ (0.05)	$ 0.03	$ (0.06)	$ 0.05	$ (0.06)	$ (1.72)